SEC Filing Summary: BioSig Technologies, Inc.
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. on October 29, 2015, covering events occurring on October 23, 2015, and October 29, 2015. The filing discloses the entry into material definitive agreements regarding a private placement of equity securities.
Key Financial Metrics
The filing details a specific capital raise event rather than periodic financial performance metrics.
- Capital Raised (Initial Closing): $430,000 aggregate consideration.
- Securities Issued: 286,666.66 Units.
- Unit Composition: One share of Common Stock and one warrant to purchase 0.5 shares of Common Stock per Unit.
- Warrant Exercise Price: $1.95 per share.
- Warrant Term: Three years from issuance.
- Future Commitment: A Unit Purchase Agreement allows for the sale of up to $7,000,000.50 of additional Units through December 31, 2015 (potentially extendable to March 31, 2016).
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change is the execution of Subscription Agreements and a Unit Purchase Agreement with accredited investors. This represents a significant increase in authorized equity capital and potential future dilution through the issuance of warrants and the potential sale of up to $7 million in additional units.
Outlook, Risks, and Contingencies
Management Commentary: The Company has secured initial funding and established a framework for additional capital raises through the end of 2015 or early 2016.
Risks and Contingencies:
- Dilution: The issuance of shares and warrants with anti-dilution protections may dilute existing shareholders.
- Registration Rights: The Company agreed to provide registration rights for the Investor Shares and shares issuable upon warrant exercise, which may impact future public offerings.
- Extension Contingency: The extension of the Unit Purchase Agreement deadline to March 31, 2016, requires the consent of both the Company and Laidlaw & Co. (UK) Ltd.
Investor Verification Checklist
- Verify the total number of Units sold under the Unit Purchase Agreement as of the most recent date.
- Confirm the current cash balance and burn rate to assess the necessity of the remaining $7 million commitment.
- Review the full text of the Registration Rights Agreement (Exhibit 10.4) to understand the scope of future registration obligations.
- Check for any subsequent filings regarding the extension of the Unit Purchase Agreement deadline.
- Confirm the exercise status of the Investor Warrants issued in the initial $430,000 closing.